摘要 |
<p>This invention relates to pharmaceutical compositions and methods of treatment utilizing a PTPase (protein-tyrosine phosphatase) inhibitors and an antilipemic agent, such as a bile acid sequestrants, a fibric acid derivative, an HMG-CoA reductase inhibitors, lipase inhibitor or a nicotinic acid derivative, to lower the risk of cardiovascular disease and cardiovascular events in a mammal experiencing or subject to type II diabetes in mammals experiencing or subject to type II diabetes (non-insulin-dependent diabetes mellitus), preferably in human type II diabetics, or in a mammal experiencing or subject to Syndrome X.</p> |